UK markets closed
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • FTSE 250

    22,522.18
    +50.18 (+0.22%)
     
  • AIM

    1,254.25
    +6.12 (+0.49%)
     
  • GBP/EUR

    1.1547
    +0.0036 (+0.31%)
     
  • GBP/USD

    1.3832
    +0.0047 (+0.34%)
     
  • BTC-GBP

    40,575.26
    -4,007.98 (-8.99%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.67 (+0.48%)
     
  • CRUDE OIL

    63.07
    -0.06 (-0.10%)
     
  • GOLD FUTURES

    1,777.30
    -2.90 (-0.16%)
     
  • NIKKEI 225

    29,683.37
    +40.67 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.61 (+0.61%)
     
  • DAX

    15,459.75
    +204.45 (+1.34%)
     
  • CAC 40

    6,287.07
    +52.93 (+0.85%)
     

Hunter Syndrome Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

·3-min read

The "Hunter Syndrome - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Hunter Syndrome - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Hunter Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hunter Syndrome Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Hunter Syndrome and Severity-based Diagnosed Prevalent Population of Hunter Syndrome in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Hunter Syndrome Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of Hunter Syndrome in the 7 major markets was found to be 1,145 in 2017. In case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 503 in 2017.

  • In the EU5 countries the diagnosed prevalence of Hunter Syndrome was found to be maximum in Germany with 83 cases, followed by the United Kingdom with 68 cases in 2017. While, the least number of cases were found in Spain, in 2017. The trend is expected to increase during the forecast period.

  • In Japan, the diagnosed prevalence of Hunter Syndrome was found to be 309 in 2017, resulting into the second highest after the US across the 7MM. MPS II is very common in Asian countries, such as Japan, Korea, China, and Taiwan.

Scope of the Report

  • The report covers the descriptive overview of Hunter Syndrome, explaining its causes, signs and symptoms, pathophysiology.

  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Hunter Syndrome.

  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Hunter Syndrome and Severity-based Diagnosed Prevalent Population of Hunter Syndrome.

Report Highlights

  • Eleven Year Forecast of Hunter Syndrome

  • 7MM Coverage

  • Total Diagnosed Prevalent Population of Hunter Syndrome

  • The publisher has also analyzed severity-sepecific diagnosed prevalence of Hunter Syndrome. Hunter Syndrome can be divided based on severity, namely, severe type (early-onset) and mild type (late). Severe MPS II onset is typically at 2-4 years of age has profound neurological problems and cognitive impairment by the age of 6 years, and death within the first two decades of life. While the 'attenuated' or mild phenotype may be associated with somatic features, patients with it generally have slight neurological involvement, are of normal intelligence, and usually survive into adulthood.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Hunter Syndrome?

  • What is the historical Hunter Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

  • What would be the forecasted patient pool of Hunter Syndrome at the 7MM level?

  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hunter Syndrome?

  • Out of the above-mentioned countries, which country would have the highest prevalent population of Hunter Syndrome during the forecast period (2020-2030)?

  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

For more information about this report visit https://www.researchandmarkets.com/r/ud7hrq

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005534/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900